Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen

Summary The treatment of transwomen relies on the combined administration of anti‐androgens or GnRH analogues to suppress androgen production and thereby reduce male phenotypic characteristics together with oestrogens to develop female characteristics. In transwomen, synthetic oestrogens such as eth...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 2015-11, Vol.83 (5), p.607-615
Main Authors: Meriggiola, Maria Cristina, Gava, Giulia
Format: Article
Language:English
Subjects:
Androgen Antagonists - administration & dosage
Androgen Antagonists - adverse effects
Breast cancer
Estrogens - administration & dosage
Estrogens - adverse effects
Female
Feminization - chemically induced
Fertility Preservation
Gender Dysphoria - drug therapy
Humans
Male
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4244-896b0b770d69892992038d9da9862dc9784c12b74058c0b652659e69480d9eca3
cites cdi_FETCH-LOGICAL-c4244-896b0b770d69892992038d9da9862dc9784c12b74058c0b652659e69480d9eca3
container_end_page 615
container_issue 5
container_start_page 607
container_title Clinical endocrinology (Oxford)
container_volume 83
creator Meriggiola, Maria Cristina
Gava, Giulia
description Summary The treatment of transwomen relies on the combined administration of anti‐androgens or GnRH analogues to suppress androgen production and thereby reduce male phenotypic characteristics together with oestrogens to develop female characteristics. In transwomen, synthetic oestrogens such as ethinyl oestradiol, as well as conjugated equine oestrogens (CEE), should be avoided to minimize thromboembolic risks especially in older transwomen and in those with risk factors. Currently, available short‐ and long‐term safety studies suggest that cross‐sex hormonal therapy (CHT) can be considered safe in transwomen improving the well‐being and quality of life of these individuals. Long‐term monitoring should aim to decrease cardiovascular risks and should include prostate and breast cancer screenings.
doi_str_mv 10.1111/cen.12754
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1815699933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1815699933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4244-896b0b770d69892992038d9da9862dc9784c12b74058c0b652659e69480d9eca3</originalsourceid><addsrcrecordid>eNqFkUtr3DAUhUVpaaZpF_0DRdBNC_VElmw9lmGYTIYOKZQ-lkKWr6lTW3IlO5NAfnyUcZJFofRu7uY7h3vPQehtTpZ5mhMLbplTURbP0CJnvMwo5eVztCCMkIxwXhyhVzFeEkJKScRLdERLrqiUdIFu1672NrQOsDUBsG_wGIyLA_ihAzyYMOLtdolPcYCrFvb3gA0-xizCNf7lQ--d6ZIGzNiDG-Mn7KfR-h4iNq7Gpr6CEAFD04AdI27d7L9PhHuNXjSmi_DmYR-j72frb6vzbPdls12d7jJb0KLIpOIVqYQgNVdSUaUoYbJWtVGS09oqIQub00oU6T1LKl6m7xVwVUhSK7CGHaMPs-8Q_J8J4qj7NlroOuPAT1HnMk-BKMXY_1FByzJnKe2Evv8LvfRTSGkcKCYFTfcl6uNMHVIL0OghtL0JNzon-r49ndrTh_YS--7Bcap6qJ_Ix7oScDID-7aDm3876dX64tEymxVtHOH6SWHCb80FE6X-ebHRxefN1x_nZzvN2B0dZLFo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1723872986</pqid></control><display><type>article</type><title>Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Meriggiola, Maria Cristina ; Gava, Giulia</creator><creatorcontrib>Meriggiola, Maria Cristina ; Gava, Giulia</creatorcontrib><description>Summary The treatment of transwomen relies on the combined administration of anti‐androgens or GnRH analogues to suppress androgen production and thereby reduce male phenotypic characteristics together with oestrogens to develop female characteristics. In transwomen, synthetic oestrogens such as ethinyl oestradiol, as well as conjugated equine oestrogens (CEE), should be avoided to minimize thromboembolic risks especially in older transwomen and in those with risk factors. Currently, available short‐ and long‐term safety studies suggest that cross‐sex hormonal therapy (CHT) can be considered safe in transwomen improving the well‐being and quality of life of these individuals. Long‐term monitoring should aim to decrease cardiovascular risks and should include prostate and breast cancer screenings.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/cen.12754</identifier><identifier>PMID: 25692882</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Androgen Antagonists - administration &amp; dosage ; Androgen Antagonists - adverse effects ; Breast cancer ; Estrogens - administration &amp; dosage ; Estrogens - adverse effects ; Female ; Feminization - chemically induced ; Fertility Preservation ; Gender Dysphoria - drug therapy ; Humans ; Male</subject><ispartof>Clinical endocrinology (Oxford), 2015-11, Vol.83 (5), p.607-615</ispartof><rights>2015 John Wiley &amp; Sons Ltd</rights><rights>2015 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2015 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4244-896b0b770d69892992038d9da9862dc9784c12b74058c0b652659e69480d9eca3</citedby><cites>FETCH-LOGICAL-c4244-896b0b770d69892992038d9da9862dc9784c12b74058c0b652659e69480d9eca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25692882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meriggiola, Maria Cristina</creatorcontrib><creatorcontrib>Gava, Giulia</creatorcontrib><title>Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol</addtitle><description>Summary The treatment of transwomen relies on the combined administration of anti‐androgens or GnRH analogues to suppress androgen production and thereby reduce male phenotypic characteristics together with oestrogens to develop female characteristics. In transwomen, synthetic oestrogens such as ethinyl oestradiol, as well as conjugated equine oestrogens (CEE), should be avoided to minimize thromboembolic risks especially in older transwomen and in those with risk factors. Currently, available short‐ and long‐term safety studies suggest that cross‐sex hormonal therapy (CHT) can be considered safe in transwomen improving the well‐being and quality of life of these individuals. Long‐term monitoring should aim to decrease cardiovascular risks and should include prostate and breast cancer screenings.</description><subject>Androgen Antagonists - administration &amp; dosage</subject><subject>Androgen Antagonists - adverse effects</subject><subject>Breast cancer</subject><subject>Estrogens - administration &amp; dosage</subject><subject>Estrogens - adverse effects</subject><subject>Female</subject><subject>Feminization - chemically induced</subject><subject>Fertility Preservation</subject><subject>Gender Dysphoria - drug therapy</subject><subject>Humans</subject><subject>Male</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFkUtr3DAUhUVpaaZpF_0DRdBNC_VElmw9lmGYTIYOKZQ-lkKWr6lTW3IlO5NAfnyUcZJFofRu7uY7h3vPQehtTpZ5mhMLbplTURbP0CJnvMwo5eVztCCMkIxwXhyhVzFeEkJKScRLdERLrqiUdIFu1672NrQOsDUBsG_wGIyLA_ihAzyYMOLtdolPcYCrFvb3gA0-xizCNf7lQ--d6ZIGzNiDG-Mn7KfR-h4iNq7Gpr6CEAFD04AdI27d7L9PhHuNXjSmi_DmYR-j72frb6vzbPdls12d7jJb0KLIpOIVqYQgNVdSUaUoYbJWtVGS09oqIQub00oU6T1LKl6m7xVwVUhSK7CGHaMPs-8Q_J8J4qj7NlroOuPAT1HnMk-BKMXY_1FByzJnKe2Evv8LvfRTSGkcKCYFTfcl6uNMHVIL0OghtL0JNzon-r49ndrTh_YS--7Bcap6qJ_Ix7oScDID-7aDm3876dX64tEymxVtHOH6SWHCb80FE6X-ebHRxefN1x_nZzvN2B0dZLFo</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Meriggiola, Maria Cristina</creator><creator>Gava, Giulia</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201511</creationdate><title>Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen</title><author>Meriggiola, Maria Cristina ; Gava, Giulia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4244-896b0b770d69892992038d9da9862dc9784c12b74058c0b652659e69480d9eca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Androgen Antagonists - administration &amp; dosage</topic><topic>Androgen Antagonists - adverse effects</topic><topic>Breast cancer</topic><topic>Estrogens - administration &amp; dosage</topic><topic>Estrogens - adverse effects</topic><topic>Female</topic><topic>Feminization - chemically induced</topic><topic>Fertility Preservation</topic><topic>Gender Dysphoria - drug therapy</topic><topic>Humans</topic><topic>Male</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meriggiola, Maria Cristina</creatorcontrib><creatorcontrib>Gava, Giulia</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meriggiola, Maria Cristina</au><au>Gava, Giulia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol</addtitle><date>2015-11</date><risdate>2015</risdate><volume>83</volume><issue>5</issue><spage>607</spage><epage>615</epage><pages>607-615</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><abstract>Summary The treatment of transwomen relies on the combined administration of anti‐androgens or GnRH analogues to suppress androgen production and thereby reduce male phenotypic characteristics together with oestrogens to develop female characteristics. In transwomen, synthetic oestrogens such as ethinyl oestradiol, as well as conjugated equine oestrogens (CEE), should be avoided to minimize thromboembolic risks especially in older transwomen and in those with risk factors. Currently, available short‐ and long‐term safety studies suggest that cross‐sex hormonal therapy (CHT) can be considered safe in transwomen improving the well‐being and quality of life of these individuals. Long‐term monitoring should aim to decrease cardiovascular risks and should include prostate and breast cancer screenings.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25692882</pmid><doi>10.1111/cen.12754</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-0664
ispartof Clinical endocrinology (Oxford), 2015-11, Vol.83 (5), p.607-615
issn 0300-0664
1365-2265
language eng
recordid cdi_proquest_miscellaneous_1815699933
source Wiley-Blackwell Read & Publish Collection
subjects Androgen Antagonists - administration & dosage
Androgen Antagonists - adverse effects
Breast cancer
Estrogens - administration & dosage
Estrogens - adverse effects
Female
Feminization - chemically induced
Fertility Preservation
Gender Dysphoria - drug therapy
Humans
Male
title Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A36%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endocrine%20care%20of%20transpeople%20part%20II.%20A%20review%20of%20cross-sex%20hormonal%20treatments,%20outcomes%20and%20adverse%20effects%20in%20transwomen&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Meriggiola,%20Maria%20Cristina&rft.date=2015-11&rft.volume=83&rft.issue=5&rft.spage=607&rft.epage=615&rft.pages=607-615&rft.issn=0300-0664&rft.eissn=1365-2265&rft_id=info:doi/10.1111/cen.12754&rft_dat=%3Cproquest_cross%3E1815699933%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4244-896b0b770d69892992038d9da9862dc9784c12b74058c0b652659e69480d9eca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1723872986&rft_id=info:pmid/25692882&rfr_iscdi=true